The Hindu Business Line : Friday, June 24, 2005

India's drawbacks
THERE have been copious writings comparing India and China and discussing why one or the other is more or less attractive as an investment destination in the eyes of foreign observers. Such theories often hinge on an ... More

ZERO BASE

Drug trial is a three-legged stool
WHEN one news headline reads, `Cop accused of bribery by witness in drug trial', and another announces, `Fertility drug trial bears joyful fruit', it is obvious that the phrase `drug trial' is yet to settle down. For ... More

EAR TO THE GROUND

Glenmark up on milestone payment talk
THE Glenmark Pharmaceuticals stock is in the buzz on market talk that it would get first milestone payment for its anti-diabetic drug research. On Thursday, the counter attracted a traded quantity of around 3 lakh shares on the BSE and finished ... More

ON THE HEDGE

Small reversal likely in HCL Tech, Tata Motors
THE following strategies are based on Thursday's trading in the derivatives segment on the NSE. These strategies are constructed to take advantage of small reversal in futures prices. The positions may run counter to the primary trend. Protective ... More

SENSOR

IT stocks dampen sentiment; mid-caps gain
AFTER scaling new life highs over the past week, both the bellwether indices took a breather on Thursday, as they closed almost flat. The BSE Sensex closed the day at 7119.7 points, shedding about 26 points in value; while the Nifty lost 4 ... More

Comments & Letters to the Editor to: bleditor@thehindu.co.in
Subscribe to: Business Line

Pick a Winner Stock Market Contest

Foster's signs up local bottling partner

MTNL withdraws Rs 1,500-cr tender for 3G equipment

A tribute to George Dantzig — To him, impossible was nothing

Now, a Hutch mobile package for Rs 1,698

States yet to claim for revenue loss from VAT implementation — It is 'early days', caution Ministry officials

Bajaj, Hero Honda, Enfield top customer satisfaction: Study

Cabinet okays Bill on alternative medicines

In Focus

BHEL Disinvestment

China's revaluation